Cost effectiveness of trivalent and quadrivalent influenza vaccines in 50- to 64-year-old adults in Korea

Choi, Eun Joung; Park, Joo Hee; Chun, Byung Chul

doi:10.1016/j.vaccine.2020.05.065

Cited by 7 publications

(4 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Age 50–64 years: In seven of the eight studies identified that specifically analyzed this age group [ 138 146 147 148 149 150 151 152 ], IV was cost-effective for outpatient or hospitalized ILI events, pneumonia, and death. Four of the studies included CV outcomes.…”

Section: Resultsmentioning

confidence: 99%

Influenza Vaccination for the Prevention of Cardiovascular Disease in the Americas: Consensus document of the Inter-American Society of Cardiology and the Word Heart Federation

Liprandi

Zaidel

et al. 2021

Global Heart

View full text Add to dashboard Cite

Background: Cardiovascular mortality is decreasing but remains the leading cause of death world-wide. Respiratory infections such as influenza significantly contribute to morbidity and mortality in patients with cardiovascular disease. Despite of proven benefits, influenza vaccination is not fully implemented, especially in Latin America. Objective: The aim was to develop a regional consensus with recommendations regarding influenza vaccination and cardiovascular disease. Methods: A multidisciplinary team composed by experts in the management and prevention of cardiovascular disease from the Americas, convened by the Inter-American Society of Cardiology (IASC) and the World Heart Federation (WHF), participated in the process and the formulation of statements. The modified RAND/UCLA methodology was used. This document was supported by a grant from the WHF. Results: An extensive literature search was divided into seven questions, and a total of 23 conclusions and 29 recommendations were achieved. There was no disagreement among experts in the conclusions or recommendations. Conclusions: There is a strong correlation between influenza and cardiovascular events. Influenza vaccination is not only safe and a proven strategy to reduce cardiovascular events, but it is also cost saving. We found several barriers for its global implementation and potential strategies to overcome them.

show abstract

Section: Resultsmentioning

confidence: 99%

Influenza Vaccination for the Prevention of Cardiovascular Disease in the Americas: Consensus document of the Inter-American Society of Cardiology and the Word Heart Federation

Liprandi

Zaidel

et al. 2021

Global Heart

View full text Add to dashboard Cite

show abstract

“…The value was also comparable with another study conducted in Spain whereby QALY lost in the elderly aged 65 years and above was at 0.0061 47 . The application of disutility value from UK and other high-income countries was also utilized by the Korean and Thailand studies 21 , 48 . Nevertheless, the multiple-one-way sensitivity analysis also demonstrated this parameter had limited impact on the ICER result.…”

Section: Discussionmentioning

confidence: 99%

“…Across the Asia–Pacific region, several cost-effectiveness studies have been conducted in the use of influenza vaccine in the elderly 18 – 20 . For instance, a Korean study reported that the inclusion of influenza vaccines in the National Immunization Program (NIP) for those aged 50–64 years was cost effective, with QIVs emerging as the preferred option based on its greater protection against influenza B 21 . To the best of our knowledge, no cost-effectiveness analysis of the influenza vaccine has been performed in Malaysia.…”

Section: Introductionmentioning

confidence: 99%

Cost effectiveness of quadrivalent influenza vaccines in the elderly population of Malaysia

Aljunid,

Mad Tahir,

Ismail

et al. 2023

Sci Rep

View full text Add to dashboard Cite

The economic burden of influenza is a significant issue within healthcare system, related to higher medical costs particularly among the elderly. Yet, influenza vaccination rates in the elderly in Malaysia were considerably low as it is not part of Malaysia’s national immunization program, with substantial mortality and morbidity consequences. Therefore, we conducted a cost-effectiveness analysis of quadrivalent influenza vaccine (QIV) for the elderly in Malaysia compared with the current no-vaccination policy. A static cost-utility model, with a lifetime horizon based on age, was used for the analysis to assess the cost-effectiveness and health outcomes associated with QIV. Univariate and probabilistic sensitivity analyses were performed to test the effects of variations in the parameters. The use of QIV in Malaysia’s elderly population would prevent 66,326 potential influenza cases and 888 potential deaths among the elderly, leading to 10,048 potential quality-adjusted life years (QALYs) gained. The QIV would also save over USD 4.4 million currently spent on influenza-related hospitalizations and reduce productivity losses by approximately USD 21.6 million. The ICER per QALY gained from a third-party payer’s perspective would be USD 2216, which is lower than the country’s gross domestic product per capita. A QIV-based vaccination program in the elderly was found to be highly cost-effective, therefore would reduce the financial burden of managing influenza and reduce pre-mature death related to this disease.

show abstract

“…16 Vaccination of the 50–64 age-group has been found to be cost effective. 25–28 Evidence suggests that the expantion of the influenza vaccination program beyond the targeted population may constitute an alternative strategy to reduce the burden of influenza, resulting in an overall higher vaccination uptake and in an easier implementation than a risk-based recommendation. 21 , 24 , 29 However, in Italy, vaccination coverage in the 2019–2020 season was only 54.6% among subjects over 65 years of age, 16.8% in the general population and even lower (9.6%) among those aged 45–64 years.…”

Section: Introductionmentioning

confidence: 99%

The burden of influenza and the role of influenza vaccination in adults aged 50-64 years: A summary of available evidence

Marchi,

Fallani,

Salvatore

et al. 2023

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Influenza is a vaccine-preventable disease and a global public health problem. Although most national influenza vaccination recommendations focus on subjects aged ≥65 years, an extensive burden of influenza has also been reported in those aged ≥50 years and is exacerbated by immune system aging. The main purpose of this review is to provide an overview of the burden of influenza and its potential prevention within the 50–64 age-group. These subjects account for a large proportion of the workforce, and play a central economic and social role. Individuals aged 50–64 years had a 3-times higher rate of hospitalization and a 9-fold higher mortality rate attributable to influenza than those aged 18–49-years, generating higher influenza-related hospitalization costs. Available data suggest that including healthy subjects aged 50–64 years in influenza vaccination recommendations would allow a broader population to be reached, reducing the economic and social burden of influenza.

show abstract

Cost effectiveness of trivalent and quadrivalent influenza vaccines in 50- to 64-year-old adults in Korea

Cited by 7 publications

References 15 publications

Influenza Vaccination for the Prevention of Cardiovascular Disease in the Americas: Consensus document of the Inter-American Society of Cardiology and the Word Heart Federation

Influenza Vaccination for the Prevention of Cardiovascular Disease in the Americas: Consensus document of the Inter-American Society of Cardiology and the Word Heart Federation

Cost effectiveness of quadrivalent influenza vaccines in the elderly population of Malaysia

The burden of influenza and the role of influenza vaccination in adults aged 50-64 years: A summary of available evidence

Contact Info

Product

Resources

About